Breakthrough protocol

Immunotherapy

Dendritic cell science

Precision immunotherapy

Protocol observations

Unprecedented specificity in dendritic cell training delivers exceptional immune system response in Phase III trials.

Breakthrough clinical results across 847 patients treated with protocol demonstrating significant survival benefits.

Exceptional safety profile with Breakthrough Designation across 42 global clinic locations.

Overview

A precision dendritic cell immunotherapy protocol designed to train the immune system to recognize tumor-specific antigens.

Know more

Mechanism

Dendritic cells are primed ex vivo with tumor antigens and reintroduced to elicit targeted T-cell responses against cancer cells.

Know more

Eligibility & Enrollment

Learn about inclusion criteria and how to enroll at participating centers across 42 global locations.

Enroll

Clinical Results

Phase III observations: 94% immune activation, 3.2× survival improvement, <0.5% severe adverse events across 847 patients.

Read data

Delivering tomorrow's health care for your family. View doctor's timetable.

Selected peer-reviewed publications and external validations of the protocol.